---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-067978"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:32:25.689615+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Codexis appoints Cynthia Collins to Board of Directors as Class II director

## Summary
- Appointed effective March 28, 2025 as Class II director; term expires at 2027 annual meeting.
- Board determined Collins is independent under Nasdaq rules; appointed to Compensation Committee.
- Previously CEO of Editas Medicine (2019-2021); currently Executive Chair/Interim CEO of Nutcracker Therapeutics.
- Receives $50k annual cash retainer plus $20k for committee; initial RSU grant of ~$200k vesting over 3 years.

## SEC filing metadata
- accession: 0001193125-25-067978
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000119312525067978/0001193125-25-067978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000119312525067978/d915487d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-067978
- JSON: https://secwatch.observer/filing/0001193125-25-067978.json
- Plain text: https://secwatch.observer/filing/0001193125-25-067978.txt

## Key facts
- Executive change
  Cynthia Collins was appointed as Member of the Board, Class II Director at CODEXIS, INC..
  - Action: appointed
  - Role: Member of the Board, Class II Director
  source text: On March 28, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Cynthia Collins as a member of the Board as a Class II director, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1200375/000119312525067978/0001193125-25-067978-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.